Cargando…

Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report

For patients with locally unresectable recurrent nasopharyngeal carcinoma who relapsed after 2 years of radiotherapy, re-radiotherapy is also the preferred treatment. However, for patients relapsed within 2 years, the use of re-radiotherapy would be greatly limited by its adverse effects. Consequent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Jiwei, Ye, Wanli, Wu, Dongping, Liu, Jianjiang, Li, Ting, Ma, Weili, Zhou, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374946/ https://www.ncbi.nlm.nih.gov/pubmed/37521461 http://dx.doi.org/10.3389/fphar.2023.1166809

Ejemplares similares

Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study
por: Liu, Jianjiang, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma
por: Wu, Dongping, et al.
Publicado: (2022)

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
por: Wang, Gangyang, et al.
Publicado: (2022)

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
por: Chen, Weimou, et al.
Publicado: (2021)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
por: Qi, Wenbo, et al.
Publicado: (2023)

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review
por: Zou, Xiaomeng, et al.
Publicado: (2023)

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
por: Yan, Le, et al.
Publicado: (2023)

Central retinal vein occlusion with cerebral infarction secondary to anlotinib treatment: a case report and literature review
por: Chen, Yingying, et al.
Publicado: (2023)

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
por: Fang, Yu, et al.
Publicado: (2023)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Positive response of a recurrent clear cell sarcoma to anlotinib combined with chemotherapy: A case report
por: Tao, Junyue, et al.
Publicado: (2022)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Frontiers Production Office,
Publicado: (2022)

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study
por: Yin, Jun, et al.
Publicado: (2023)

Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
por: Cheng, Ke, et al.
Publicado: (2022)

Investigation on the Efficiency of Chinese Herbal Injections combined with Concurrent Chemoradiotherapy for Treating Nasopharyngeal Carcinoma based on Multidimensional Bayesian Network Meta-analysis
por: Wu, Zhishan, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
por: Li, Shuo, et al.
Publicado: (2023)

Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
por: Jin, Caibao, et al.
Publicado: (2020)

Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report
por: Wu, Ying, et al.
Publicado: (2023)

Effect of Chinese Herbal Medicine Therapy on Overall and Cancer Related Mortality in Patients With Advanced Nasopharyngeal Carcinoma in Taiwan
por: Wang, Chen-Yu, et al.
Publicado: (2021)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023)

A Short-Term Efficacy of Anlotinib in the Treatment of Refractory Nasopharyngeal Inverted Papilloma: A Case Report
por: Yang, Pan, et al.
Publicado: (2021)

Increased Angiogenin Expression Correlates With Radiation Resistance and Predicts Poor Survival for Patients With Nasopharyngeal Carcinoma
por: Guo, Shan-Shan, et al.
Publicado: (2021)

Brevilin A Induces Cell Cycle Arrest and Apoptosis in Nasopharyngeal Carcinoma
por: Liu, Rui, et al.
Publicado: (2019)

Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer
por: Tan, Tingfei, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
por: Wen, Yingmei, et al.
Publicado: (2023)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

Effectiveness Comparisons of Drug Therapy on Chronic Subdural Hematoma Recurrence: A Bayesian Network Meta-Analysis and Systematic Review
por: Yu, Wanli, et al.
Publicado: (2022)

Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
por: Ji, Xiang, et al.
Publicado: (2022)

Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
por: Li, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1mrfbujc0nev15m8n6ku0v9b4n